Reporting of acute urinary retention in BPH treatment trials: Importance of patient follow-up after discontinuation and case definitions

Urology

Volumn 59, Issue 6, 2002, Pages 811-815

  Roehrborn, Claus G ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FINASTERIDE; PLACEBO; TAMSULOSIN; TERAZOSIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; URINE RETENTION;

ACUTE DISEASE; ADRENERGIC ALPHA-ANTAGONISTS; ENZYME INHIBITORS; FINASTERIDE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS; URINARY RETENTION;

EID: 0036096914     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)01649-7     Document Type: Article

References (17)

1. Natural history of prostatism: Risk factors for acute urinary retention
2. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia
3. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years: Characterization of patients and outcomes
4. Alfuzosin for treatment of benign prostatic hypertrophy
5. The natural history of benign prostatic hypertrophy: Incidence of urinary retention and significance of AUA symptom score
6. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia
7. Results of the PREDICT (Prospective European Doxazosin and Combination Therapy) trial
8. Benign prostatic obstruction complications and need for surgery
9. Meta-analysis of alpha-blocker effects on acute urinary retention (AUR)
10. Do α-blockers affect the progression of benign prostatic hyperplasia
11. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia
12. Can finasteride reverse the progress of benign prostatic hyperplasia? A 2-year placebo-controlled study
13. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: Results of a 2-year randomized controlled trial (the PROSPECT study)
14. Long-term effects of finasteride in patients with benign prostatic hyperplasia: A double-blind, placebo-controlled, multicenter study
15. A one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia
16. A 6-month large-scale study into the safety of tamsulosin
17. Baseline patient characteristics in the NIH BPH trial